<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648608</url>
  </required_header>
  <id_info>
    <org_study_id>TENBC</org_study_id>
    <nct_id>NCT01648608</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy
      and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as neoadjuvant
      chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX 600mg/m2,21day/cycle).At the
      same time give daily oral exemestane 25mg for 12 weeks.Then assess the efficacy and safety of
      TAC and Exemestane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators select the postmenopausal patients with breast cancer who is confirmed by
      core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as
      neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX
      600mg/m2,21day/cycle).At the same time give daily oral exemestane 25mg for 12 weeks.Then
      assess the efficacy and safety of TAC and Exemestane.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapeutic assessment</measure>
    <time_frame>6 months</time_frame>
    <description>therapeutic assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions and disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse reactions and disease-free survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence or death</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence or death</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exemestane for neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane for neoadjuvant chemotherapy</description>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Karnofsky ≥ 70

          2. Provision of informed consent

          3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is
             positive

          4. Tumor stage(TNM):T2-4bN0-3M0

          5. Premenopausal woman

          6. Not previously received treatment with bisphosphonate

          7. Laboratory criteria:

               -  PLT ≥ 100*109/L

               -  WBC ≥ 4000/mm3

               -  HGB ≥ 10g/dl

               -  GOT,GPT,ALP ≤ 2*ULN

               -  TBIL,DBIL,CCr ≤ 1.5*ULN

        Exclusion Criteria:

          1. Pregnant or lactation woman

          2. History of organ transplantation

          3. With mental disease

          4. With severe infection or active gastrointestinal ulcers

          5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or
             diabetes

          6. Disease-free period of other malignant tumor is less than 5 years(except cured basal
             cell skin cancer and cervical carcinoma in situ)

          7. With heart disease

          8. Experimental drug allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jin Zhang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin cancer hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHANG SHENG, DOCTOR</last_name>
      <phone>86-022-23340123</phone>
      <phone_ext>2901</phone_ext>
    </contact>
    <contact_backup>
      <last_name>ZHANG SHENG, DORTOR</last_name>
      <phone>86-022-23340123</phone>
      <phone_ext>2901</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>ZHANG JIN, PROFESSOR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University</investigator_affiliation>
    <investigator_full_name>Zhang jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

